SCHEMBL1019835

SCHEMBL1019835

C(#Cc1ccc(OC2CN3CCC2CC3)nn1)c1ccc2[nH]ccc2c1

nearest known ligand 0.67

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 5/20 0.67
CHRNB2 P17787 4/20 0.42
CHRNA4 P43681 4/20 0.42
HTR3A P46098 1/20 0.42
CHRNB4 P30926 3/20 0.38
CHRNA3 P32297 3/20 0.38
GRIN1 Q05586 1/20 0.37
GFER P55789 1/20 0.37
APP P05067 1/20 0.35
IMPDH2 P12268 1/20 0.34
IMPDH1 P20839 1/20 0.34
OGA O60502 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1018526 0.85 CHRNA7 (0.46) CHRNA7
SCHEMBL1018315 0.82 CHRNA7 (0.44) CHRNA7
Abt-107 SCHEMBL373047 0.80 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4HTR3ACHRNB4
Abt-107 SCHEMBL527745 0.80 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4HTR3ACHRNB4
Abt-107 SCHEMBL1542259 0.80 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4HTR3ACHRNB4
Abt-107 SCHEMBL31393053 0.80 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4HTR3ACHRNB4
Abt-107 SCHEMBL29364159 0.80 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4HTR3ACHRNB4
SCHEMBL1019786 0.80 CHRNA7 (0.44) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL3080565 0.80 CHRNA7 (0.44) CHRNA7
SCHEMBL1018510 0.80 LSS (0.48) CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1802616-B1 NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH AS (DK) 2011-01-12 EP claimed
US-7652010-B2 Azabicyclic aryl derivatives and their medical use NEUROSEARCH A/S (DK) 2010-01-26 US claimed
US-20070299082-A1 Novel Azabicyclic Aryl Derivatives and Their Medical Use ANIONA APS (DK) 2007-12-27 US claimed
EP-1802616-B1 NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH AS (DK) 2011-01-12 EP disclosed
US-7652010-B2 Azabicyclic aryl derivatives and their medical use NEUROSEARCH A/S (DK) 2010-01-26 US disclosed
US-20070299082-A1 Novel Azabicyclic Aryl Derivatives and Their Medical Use ANIONA APS (DK) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299082-A1 Novel Azabicyclic Aryl Derivatives and Their Medical Use CHRNA6, CHRNA10, CHRNA5 CHRNA7 6/4885CHRNB2 8/4885CHRNA4 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.